Literature DB >> 18055253

Detection of human influenza A (H1N1) and B strains with reduced sensitivity to neuraminidase inhibitors.

Vanessa Escuret1, Emilie Frobert, Maude Bouscambert-Duchamp, Murielle Sabatier, Isidore Grog, Martine Valette, Bruno Lina, Florence Morfin, Olivier Ferraris.   

Abstract

BACKGROUND: Neuraminidase inhibitors (NAIs) have been used since 2005 in France.
OBJECTIVE: Influenza viruses isolated in hospital and community cases in winter 2005-2006 were evaluated for their sensitivity to NAIs. STUDY
DESIGN: Isolates were tested in duplicate with a fluorescence-based neuraminidase assay. The IC50 for oseltamivir or zanamivir was calculated for each strain. Mean IC50 (+/-S.D.) are expressed in nM. Viruses with IC50 superior or very superior to the upper limit (mean IC50+2.5 S.D.) were considered as outliers or resistant viruses, respectively. HA and NA genes for outliers, resistant strains and for a few sensitive strains were sequenced.
RESULTS: Out of 225 B isolates, one was found resistant to both oseltamivir and zanamivir with a D197Y mutation in NA and eight isolates were outliers for oseltamivir and/or zanamivir. Out of 151 A (H1N1) isolates, one was found resistant to oseltamivir but sensitive to zanamivir with a H275Y mutation in NA, two isolates were resistant to zanamivir and three isolates were outliers for oseltamivir and/or zanamivir. New mutations were detected in outliers compared to sensitive viruses.
CONCLUSION: Resistant influenza strains to NAIs are circulating at a stable and low level of 1% since the introduction of NAIs in clinical practice.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18055253     DOI: 10.1016/j.jcv.2007.10.019

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  39 in total

Review 1.  Neuraminidase inhibitors for influenza B virus infection: efficacy and resistance.

Authors:  Andrew J Burnham; Tatiana Baranovich; Elena A Govorkova
Journal:  Antiviral Res       Date:  2013-09-04       Impact factor: 5.970

2.  Fitness costs for Influenza B viruses carrying neuraminidase inhibitor-resistant substitutions: underscoring the importance of E119A and H274Y.

Authors:  Andrew J Burnham; Tatiana Baranovich; Bindumadhav M Marathe; Jianling Armstrong; Robert G Webster; Elena A Govorkova
Journal:  Antimicrob Agents Chemother       Date:  2014-02-24       Impact factor: 5.191

3.  Comparable fitness and transmissibility between oseltamivir-resistant pandemic 2009 and seasonal H1N1 influenza viruses with the H275Y neuraminidase mutation.

Authors:  Diana D Y Wong; Ka-Tim Choy; Renee W Y Chan; Sin Fun Sia; Hsin-Ping Chiu; Peter P H Cheung; Michael C W Chan; J S Malik Peiris; Hui-Ling Yen
Journal:  J Virol       Date:  2012-07-18       Impact factor: 5.103

4.  In vitro selection of influenza B viruses with reduced sensitivity to neuraminidase inhibitors.

Authors:  S Hatakeyama; M Ozawa; Y Kawaoka
Journal:  Clin Microbiol Infect       Date:  2010-07-15       Impact factor: 8.067

5.  Competitive fitness of influenza B viruses with neuraminidase inhibitor-resistant substitutions in a coinfection model of the human airway epithelium.

Authors:  Andrew J Burnham; Jianling Armstrong; Anice C Lowen; Robert G Webster; Elena A Govorkova
Journal:  J Virol       Date:  2015-02-11       Impact factor: 5.103

6.  Aurintricarboxylic acid is a potent inhibitor of influenza A and B virus neuraminidases.

Authors:  Anwar M Hashem; Anathea S Flaman; Aaron Farnsworth; Earl G Brown; Gary Van Domselaar; Runtao He; Xuguang Li
Journal:  PLoS One       Date:  2009-12-17       Impact factor: 3.240

7.  Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008.

Authors:  Tiffany G Sheu; Varough M Deyde; Margaret Okomo-Adhiambo; Rebecca J Garten; Xiyan Xu; Rick A Bright; Eboneé N Butler; Teresa R Wallis; Alexander I Klimov; Larisa V Gubareva
Journal:  Antimicrob Agents Chemother       Date:  2008-07-14       Impact factor: 5.191

8.  Influenza virus resistance to antiviral agents: a plea for rational use.

Authors:  Gregory A Poland; Robert M Jacobson; Inna G Ovsyannikova
Journal:  Clin Infect Dis       Date:  2009-05-01       Impact factor: 9.079

9.  Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007-08.

Authors:  Siri H Hauge; Susanne Dudman; Katrine Borgen; Angie Lackenby; Olav Hungnes
Journal:  Emerg Infect Dis       Date:  2009-02       Impact factor: 6.883

10.  Inhibition of neuraminidase inhibitor-resistant influenza virus by DAS181, a novel sialidase fusion protein.

Authors:  Gallen B Triana-Baltzer; Larisa V Gubareva; Alexander I Klimov; David F Wurtman; Ronald B Moss; Maria Hedlund; Jeffrey L Larson; Robert B Belshe; Fang Fang
Journal:  PLoS One       Date:  2009-11-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.